Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 2004

View Archived Issues

Small molecule VEGF antagonist inhibits tumor growth in vivo

Antiviral efficacy of a saquinavir-based HAART regimen in HIV-infected patients

Significant association found between coronary artery risk factors and erectile dysfunction

Rosiglitazone improves insulin activity and affects adipose cell turnover in obese rats

CancerVax licenses rights to SAI product candidates targeting EGFR

New phase IIb study of darusentan for resistant systolic hypertension

BioMimetic's GEM-21S recommended for approval

Phase IIb study of VEGF-2 for severe cardiovascular disease cleared to begin

Rotarix vaccine receives first global approval in Mexico

Neurobiological Technologies acquires Empire Pharmaceuticals, expanding pipeline with Viprinex

NDA for Xopenex HFA MDI accepted for review

Estorra NDA resubmission accepted by FDA

Indiplon NDA filings planned for fourth quarter 2004

I2S receives fast track status for Hunter's syndrome

First phase of topical ENT-103 formulation completed

European approval for Telzir for HIV

Aldara receives approval for superficial basal cell carcinoma

WF-10 fails to meet primary endpoints in phase III AIDS study

Good safety and pharmacokinetic profile of the antiretroviral GW-695634 in healthy volunteers

Safinamide improves motor function in patients with Parkinson's disease

Update on the safety, pharmacokinetics and antiviral effects of PA-457 in HIV infection

TGF-beta inhibitor claimed in Lilly patent

Takeda discloses melanin-concentrating hormone (MCH) antagonists

Inhibitors of hepatic gluconeogenesis in early development at Sumitomo

Tyropeptin A analogues with antitumor activity disclosed in patent

PTP-1B inhibitors for the treatment of insulin resistance

Xanthine derivatives under development at Sumitomo

Preclinical efficacy in a task sensitive to Alzheimer's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...